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atrial pressure were extracted as these were deemed the
most clinically relevant outcome measures. Where possi-
ble, data was segregated according to intervention, the
type of PAH and the functional class of patients eva-
luated in the studies. RESULTS: The literature search
yielded 1503 abstracts. Of these, 54 were included after
ﬁrst pass assessment. Twenty-eight papers were included
after second pass assessment, and were extracted. The
mean Jadad score was 1.56 (range 0–5). Mean ages for
primary and secondary pulmonary arterial hypertension
were 41 and 47 respectively. Three-year survival rates
were 49% to 76% across all interventions. Mean changes
in right atrial pressure ranged from -6 to 2mmHg, whilst
mean changes in exercise capacity varied from -189 
to 132m. CONCLUSION: The variable quality of the
reviewed articles is partly due to the ethical difﬁculties in
trial design in this disease area. Quantitative comparisons
of the interventions are difﬁcult within the context of this
review, but the homogeneity of the data may make meta-
analysis of the evidence possible.
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COMORBIDITIES CAUSING INCREASING
MORTALITY AT AGES UNDER 65 
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OBJECTIVES: Identify combinations of cancer, cere-
brovascular, diabetes, respiratory, CNS, and infectious
concomitant illnesses in cardiovascular disease causing
increasing risks of dying at ages under 65 and assess sub-
sequent changes in the prevalence of these combinations.
METHODS: Combinations of multivariate linear regres-
sions and standard SAS codes were applied to data drawn
from the 1991–1996 Multiple Causes of Death Files. The
5-year numbers of deaths, cardiovascular-associated, 
and hypertension-associated deaths were 11,056,565,
and 5,486,234 (<65 = 2,769,731), and 904,770 (<65 =
166,007), respectively. RESULTS: During 1991–1996,
mortality rates in individuals with CV disease decreased:
in <65–6% and  65–3%. The prevalence of cardiovas-
cular-associated deaths has decreased from 39.6% to
39.2% of all deaths <65. The following combinations of
comorbidities in individuals <65 with cardiovascular
morbidity demonstrated increasing prevalence (PR), mor-
tality rates (MR) and relative MR of <65/  65: diabetes
(PR -12%, MR -6%, RMR -1.7%); CNS (PR -13%,
MR -8%, RMR -6%); infectious (PR -3%, MR -1%,
RMR -3%). In addition, diabetes in combination with
cerebrovascular, cancers and respiratory comorbidities
caused increased, up to 36%, risk of dying at ages under
65. A 69% (in CV+diabetes) growth of the ischaemic
heart disease case-fatality was the highest increase in 
case-fatality across all primary causes of death. In <65,
mortality rates of hypertension and with diabetes grew
14% and 26% (‘25–29’ -66%), respectively. Among 55
primary causes of death in hypertension, the highest
increase in case-fatality occurred for cns diseases (demen-
tia, psychoses, Alzheimer’s, paralysis), diabetes with renal
manifestations (115%), hypertensive heart (95%), and
respiratory diseases (COPD, pneumonia, asthma, emphy-
sema). CONCLUSION: Although cardiovascular mortal-
ity has decreased overall, disease management for patients
with cns, diabetes, and infectious comorbidities calls for
further research because these groups of patients exhibit
increasing risks of dying at the ages under 65. Related
premature mortality costs and productivity losses will be
presented.
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OBJECTIVE: Patients surviving subarachnoid haemor-
rhage (SAH) are at risk for recurrences despite initial suc-
cessful and complete treatment. A simulation model was
used to assess the merits of screening for new aneurysms
and regrowth using CT angiography. METHODS: A 
literature review yielded incidence rates of recurrent
aneurysms (regrowth and de novo), rupture and com-
plications after diagnosis and re-intervention, and the
impact of disabling cerebrovascular events in terms of
(dis-) utility. We used Markov chain Monte Carlo simu-
lation to compare “screening” and “no screening” after
a ﬁrst aneurysmal SAH. Various strategies with screening
intervals of 2, 5 and 10 years were evaluated. We esti-
mated expected quality adjusted life years (QALY’s),
number of SAHs and morbidity and mortality rates for
all strategies, including 95%CI. RESULTS: In cohort
simulations of 10.000 patients the number of QALY’s ten
years after clipping was virtually similar for “screening”
(8.26) and “no screening” (8.32). Screening every two or
ﬁves year did hardly affect the results. Screening every
two years decreased SAH from 1.9% to 0.5% and mor-
tality from 0.9% to 0.6%. The percentage of disabled
patients, however, increased from 0.5% to 1.9%. Similar
trends, i.e., slight QALY loss after screening, were seen
with remaining life expectancy as time horizon. Con-
versely, we observed a slight survival beneﬁt after screen-
ing. Screening after initial treatment with coils resulted in
comparable outcomes. CONCLUSIONS: We lack accu-
rate clinical data on incidence of recurrent aneurysms as
well as subsequent risk of rupture. Also the utility score
attributed to dependency after SAH or another compli-
cation is hardly substantiated. These parameters drive the
results of our modeling analysis. Thus, presently we can
neither recommend nor refute screening patients treated
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after a ﬁrst episode of SAH. Screening may prevent new
episodes of SAH but might also lead to higher morbidity
rates because of diagnosis and treatment related com-
plications. Further clinical studies are required to ﬁll 
the gaps detected, and costs should be balanced against
effects.
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OBJECTIVES: Stenting of the arteria carotis interna
(CAS) is becoming an increasingly popular means of
treating carotid stenosis. At present however costs of
stents are high and conclusive trials to prove the (equal)
effectiveness of CAS as compared to carotid endarterec-
tomy (CEA) are not ﬁnalized yet. The primary goal of the
current study is to assess the uncertainties concerning
long- and short-term clinical outcomes on the cost-
effectiveness analysis of CAS verses CAE. METHODS: A
Markov model was constructed to assess the cost-
effectiveness for carotid treatment for the Dutch setting
based on clinical data published in literature and in-house
collected cost data. RESULTS: The procedural costs for
the CAS procedure are 15% higher than costs for a CEA.
Major stroke is a dominating factor in both quality of life
and in follow-up costs. Therefore the short- and long-
term results of the cost-beneﬁt analysis will be highly
inﬂuenced by the perioperative and post-operative inci-
dence rates for major stroke. This idea is supported by
model sensitivity analyses who show that the sensitivity
to the long-term incidence rate is two times higher than
the short-term incidence rate. As the level of uncertainty
of the long-term major stroke rates are higher than those
of the perioperative stroke rates, these will clearly domi-
nate the level of uncertainty regarding the decision on 
the cost-effectiveness of the CAS procedure. CONCLU-
SIONS: The results show that the uncertainties concern-
ing the long-term major stroke risks have a predominant
inﬂuence on the outcome of the evaluation of the cost-
effectiveness of CAS over CEA. Therefore, long-term
effects need to be assessed and considered before a 
balanced decision on the cost-effectiveness of the CAS
over the CEA procedure can be taken.
CARDIOVASULAR DISEASES/DISORDERS—
Quality of Life
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OBJECTIVES: Patients with Heart Failure (HF) are
known to be noncompliant and can also suffer from poor
HRQoL. We wanted to determine whether compliance
inﬂuenced HRQoL scores. We used the SF-36 and com-
pliance scores of patients with HF to examine this ques-
tion. METHODS: These data are from a RCT of patients
with HF (n = 134) who were assigned to a usual care arm
(U) or an enhanced intervention arm (I) and followed for
one year. Improvement in HRQoL was considered as an
increase in 10 points in the PCS or MCS summary scales
of the SF-36, which we considered to be reﬂective of 
a minimal clinically important difference (MCID) for
patients. Patients who had an overall compliance score
between 0.8 and 1.2 were considered compliant. Patients
who had an overall compliance <0.8 or >1.2 were deemed
non-compliant. Using a logistic regression model with
compliance as the dependent variable we entered HRQoL
data and ARM allocation. RESULTS: The odds ratio of
associated with a 10-point increase in PCS was 1.63 for
compliance relative to non-compliance (CI 1.06–2.51) p
= 0.026. The odds ratio associated with a 10-point
increase in MCS was 1.26 (CI 0.868–1.83) p (ns). When
we include the ARM in the model the odds ratio is 1.58
(CI > 1.02–2.45), p = 0.040. CONCLUSIONS: There is
a statistically signiﬁcant relationship (p < 0.05) between
HRQoL and compliance, where 1.63 can be interpreted
as the change in odds of compliance relative to non-
compliance that is associated with a 10-point change in
the PCS score of the SF-36. These ﬁndings help us inter-
pret HRQoL data by including HRQoL as a mediating
variable that affects outcomes such as compliance that are
known to have a signiﬁcant impact on patients with HF.
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OBJECTIVES: Patients with HF suffer from poor health
related quality of life (HRQoL). In this randomized con-
trolled trial we used both generic (SF-36, HUI Mark 2/3)
and disease speciﬁc (MLHFQ) measures of HRQoL to
determine whether our educational intervention had any
impact on these outcomes. METHODS: Patients with 
HF were stratiﬁed by reason for admission and then 
randomized to receive either usual care (U) or an educa-
tional intervention (I). HRQoL was a secondary outcome
measure in this trial. All patients were measured at base-
line and every three months to one year. RESULTS: In 
the SF-36 there was a trend at certain visit numbers in
physical functioning (p = 0.081), role limitation due to
physical problems (p = 0.032), role limitation due to emo-
tional problems (p = 0.068) and energy vitality (p =
0.068). There were no differences over time between each
